ライフサイエンスコーパス: soft tissue infection

1 crotizing myositis, bacteremia, and skin and soft tissue infection.

2 y patterns was examined in a murine model of soft tissue infection.

3 cts of the care of patients with necrotizing soft tissue infection.

4 tants highly attenuated in a murine model of soft tissue infection.

5 ghly attenuated in the murine ulcer model of soft tissue infection.

6 anscriptome of GAS during experimental mouse soft tissue infection.

7 he pathogenesis of streptococcal necrotising soft tissue infection.

8 ted to have a minimal potential for invasive soft tissue infection.

9 lence factor for invasive disease, including soft tissue infection.

10 y and is mainly associated with subcutaneous soft tissue infection.

11 uronic acid capsule as a virulence factor in soft tissue infection.

12 sociated with enhanced virulence in skin and soft tissue infection.

13 lococcus aureus is a major cause of skin and soft tissue infection.

14 ME mutants was assessed in a murine model of soft tissue infection.

15 a less invasive form of superficial skin and soft tissue infection.

16 Haemophilus influenzae is a rare cause of soft tissue infection.

17 d pathogenesis in a murine model of skin and soft tissue infection.

18 cause of community-onset S. aureus skin and soft-tissue infection.

19 sons with community-onset S. aureus skin and soft-tissue infection.

20 luenced by covR also was identified in mouse soft-tissue infection.

21 protein in a murine model of human invasive soft-tissue infection.

22 fasciitis is a rare, but potentially fatal, soft-tissue infection.

23 elative to the odds of PVL-positive skin and soft-tissue infection.

24 tial therapeutic in SAg-mediated necrotizing soft-tissue infection.

25 l infection in a murine model of necrotizing soft-tissue infection.

26 s a role in pathogenesis in a mouse model of soft-tissue infection.

27 ossible, probable, or definite cellulitis or soft tissue infections.

28 hogen causing pulmonary disease and skin and soft tissue infections.

29 using an ongoing pandemic of mostly skin and soft tissue infections.

30 t of which (53%) were pneumonia and skin and soft tissue infections.

31 re pandemic consisting primarily of skin and soft tissue infections.

32 n the differential diagnosis of gingival and soft tissue infections.

33 014 primarily reflected declines in skin and soft tissue infections.

34 throat) and with invasive or "flesh-eating" soft tissue infections.

35 ysteine protease contributes to virulence in soft tissue infections.

36 s aureus (MRSA) is a major cause of skin and soft tissue infections.

37 s invasive disease, most frequently skin and soft tissue infections.

38 SA) causes invasive, drug-resistant skin and soft tissue infections.

39 fections and syndromes-most notably skin and soft tissue infections.

40 ng invasive disease, pneumonia, and skin and soft tissue infections.

41 empirical treatment guidelines for skin and soft-tissue infections.

42 or patients presenting with serious skin and soft-tissue infections.

43 me a predominant cause of childhood skin and soft-tissue infections.

44 eus should be considered a cause of skin and soft-tissue infections.

45 nes, a common agent of pharyngeal, skin, and soft-tissue infections.

46 nes, a common agent of pharyngeal, skin, and soft-tissue infections.

47 tates and has caused an epidemic of skin and soft-tissue infections.

48 a-analysis for Staphylococcus aureus skin or soft-tissue infections.

49 l, predominantly for abdominal, urinary, and soft-tissue infections.

50 aureus, a common cause for serious skin and soft tissues infections.

51 h methicillin-susceptible S. aureus skin and soft-tissue infection (1%).

52 nd against isolates associated with skin and soft tissue infection (68%, compared to 85% susceptible

53 lated from 320 of 422 patients with skin and soft-tissue infections (76 percent).

54 awareness of fungi as a cause of necrotizing soft-tissue infections after a natural disaster is warra

55 In a mouse model of GAS soft tissue infection, all DeltaptsI mutants exhibited a

56 ed USA300-0114, is a major cause of skin and soft tissue infections among persons in community settin

57 e most common identifiable cause of skin and soft-tissue infections among patients presenting to emer

58 s streptococcal virulence in mouse models of soft tissue infection and bacteremia.

59 Cellulitis is a commonly occurring skin and soft tissue infection and one of the most frequently see

60 for virulence in a murine model of invasive soft tissue infection and this attenuation is complement

61 frequent manifestation of S. aureus skin and soft tissue infections and are formed, in part, to conta

62 e opportunist pathogens that cause blood and soft tissue infections and are often resistant to antimi

63 ylococcus aureus is a leading cause of human soft tissue infections and bacterial sepsis.

64 We describe an HIV-infected patient with 24 soft tissue infections and multiple colonization events.

65 ble for severe, rapidly progressive skin and soft tissue infections and native valve endocarditis.

66 le for a wide range of infections, including soft tissue infections and potentially fatal bacteremias

67 ection and plays an important role in severe soft tissue infections and systemic dissemination of GAS

68 lence in vivo using mouse models of invasive soft-tissue infection and septicemia.

69 A (SPEA), in the pathogenesis of necrotizing soft-tissue infection and toxic shock syndrome resulting

70 es are consistently associated with skin and soft-tissue infections and are comparatively rare in inv

71 nderstanding of the epidemiology of skin and soft-tissue infections and osteoarticular infections is

72 cation are changing the approach to skin and soft-tissue infections and osteoarticular infections.

73 Ten cases (42%) had skin and soft tissue infection, and 2 cases had invasive disease.

74 children, NTM cause lymphadenitis, skin and soft tissue infections, and occasionally also lung disea

75 aureus is the most common cause of skin and soft tissue infections, and rapidly emerging antibiotic-

76 roup of patients presenting with necrotizing soft tissue infections, and, based on this analysis, pro

77 mutants were attenuated in a murine model of soft-tissue infection, and analysis of gene expression i

78 ezolid in the setting of pneumonia, skin and soft-tissue infections, and infections due to vancomycin

79 The mortality for necrotizing soft-tissue infections appears to be decreasing, possibl

80 sful management of patients with necrotizing soft tissue infection are early recognition and complete

81 (MyD88) deficiency, staphylococcal skin and soft tissue infections are a leading and potentially lif

82 Skin and soft tissue infections are common reasons for medical ca

83 PVL-positive skin and soft-tissue infections are more likely to be treated sur

84 Necrotizing soft-tissue infection-associated in-hospital mortality.

85 injection drug use who were readmitted with soft tissue infections at new sites (16.8% of readmissio

86 ism to explain the development of severe GAS soft-tissue infections at the sites of prior minor muscl

87 nt of streptococcal sore throat and invasive soft-tissue infections, attaches to human pharyngeal or

88 ribe an outbreak of Nocardia cyriacigeorgica soft-tissue infections attributable to unlicensed cosmet

89 aureus (CA-MRSA), a major cause of skin and soft tissue infections, became successful so quickly, ov

90 trains are strongly associated with skin and soft-tissue infections, but are comparatively rare in pn

91 We report the first case of complicated soft tissue infection caused by P. lilacinus in an immun

92 We present the first case of human skin and soft tissue infection caused by this species in a patien

93 increasing in frequency is serious bacterial soft tissue infections caused by group A streptococci.

94 Human invasive soft-tissue infections caused by group A Streptococcus a

95 idence of infections, such as RTIs; skin and soft-tissue infections; chronic comorbid conditions, inc

96 y is indicated for the treatment of skin and soft-tissue infections, clinicians should consider obtai

97 We report a soft tissue infection containing multiple pathogens, inc

98 Complicated skin and soft tissue infections (cSSTIs) are among the most rapid

99 n immunocompromised patient with an invasive soft tissue infection due to Scedosporium apiospermum wa

100 tered three patients with severe necrotising soft tissue infections due to beta-haemolytic group G st

101 egative cocco-bacillus often associated with soft tissue infections due to dog and cat bites.

102 For soft tissue infections due to molds characterized by thi

103 Community-onset skin and soft-tissue infection due to S. aureus was identified in

104 itive and most were associated with skin and soft tissue infections (especially abscesses).

105 nt of streptococcal sore throat and invasive soft tissue infections, evades internalization and intra

106 e differential diagnosis of chronic skin and soft tissue infections following bee venom acupuncture.

107 occus aureus are the major cause of skin and soft tissue infection in the United States.

108 In vivo soft tissue infection in wild-type mice demonstrated tha

109 ngal pathogen, causing a variety of skin and soft tissue infections in healthy people and more virule

110 and has become the leading cause of skin and soft tissue infections in the United States.

111 cause of as much as 98% of CA-MRSA skin and soft tissue infections in the United States.

112 (68)Ga-NOTA-UBI could diagnose bone- and soft-tissue infection in 3 of 3 patients.

113 We defined a case as a soft-tissue infection in a person injured during the tor

114 ccus aureus (MRSA) causes S. aureus skin and soft-tissue infection in selected populations.

115 o-associated Mycobacterium chelonae skin and soft-tissue infections in Rochester, New York.

116 Necrotizing soft tissue infection is a severe illness that is associ

117 The early diagnosis of necrotizing soft tissue infection is challenging, but the keys to su

118 rgan transplant recipients, localized fungal soft tissue infection is infrequent, with only 35 cases

119 ezolid has approved indications for skin and soft tissue infections; lower respiratory tract infectio

120 r as adjuncts to antibiotic therapy, for GAS soft tissue infection may contribute to worse outcomes.

121 Here we developed a skin and soft tissue infection model in rabbits to test the hypot

122 and 24 h after bacterial challenge in a rat soft tissue infection model resulted in a significant de

123 creased lesion size and severity in a murine soft tissue infection model when compared with parental

124 d with HlaH35L and challenged via a skin and soft tissue infection model, HlaH35L immunization led to

125 rvival in human serum, and survival in a rat soft tissue infection model.

126 c spyCEP mutant derivative strain in a mouse soft tissue infection model.

127 B307.27 was significantly decreased in a rat soft-tissue infection model (P<.001) and a rat pneumonia

128 Next we tested the hypothesis that the soft-tissue infection model could be used to discriminat

129 hly paralleled their growth/clearance in the soft-tissue infection model in vivo.

130 drug-resistant Acinetobacter baumannii in a soft-tissue infection model through light-triggered NO d

131 were subsequently used for challenge in the soft-tissue infection model to determine if the disrupte

132 Lastly we hypothesized that the soft-tissue infection model would serve as an efficient

133 ble to demonstrate growth of 307-0294 in the soft-tissue infection model.

134 gnificantly attenuated in the bacteremia and soft tissue infection models, and the mutant strain lack

135 ed the hypothesis that the rat pneumonia and soft-tissue infection models that our laboratory had pre

136 ically significant, with bacteremia (n = 5), soft tissue infections (n = 3) osteomyelitis (n = 2), in

137 in (PVL) are associated with severe skin and soft tissue infections, necrotizing pneumonia, and eye i

138 In mouse invasive soft-tissue infection, neither SLO or SLS expression sig

139 ortunistic pathogen associated with skin and soft tissue infections, nosocomial pneumonia and sepsis.

140 ive infections, such as necrotizing skin and soft tissue infections (NSSTI).

141 immunocompromised patients with necrotizing soft-tissue infection (NSTI).

142 Necrotizing soft-tissue infections (NSTI) have high morbidity and mo

143 ) patients, including sepsis and necrotizing soft tissue infections (NSTIs).

144 Of the 10 MRSA skin and soft tissue infections observed in this study, all occur

145 ervous System Infections, Ocular Infections, Soft Tissue Infections of the Head and Neck, Upper Respi

146 not a critical virulence factor in invasive soft-tissue infection or bacteraemia caused by S. pyogen

147 colonization, primary or recurrent skin and soft tissue infection, or invasive disease.

148 eraemia, musculoskeletal infection, skin and soft-tissue infection, or colonisation published before

149 Infections, Genital Infections, and Skin and Soft Tissue Infections; or into etiologic agent groups,

150 We report a skin and soft-tissue infection outbreak among football team membe

151 bacteremia, meningitis, pneumonia, skin and soft tissue infections, peritonitis, and urinary tract i

152 tients with invasive infections, noninvasive soft tissue infections, pharyngitis, and rheumatic fever

153 tients with invasive infections, noninvasive soft tissue infections, pharyngitis, and rheumatic fever

154 adult patients with acute, purulent skin and soft-tissue infections presenting to 11 university-affil

155 uced and (2) many strains of MSSA that cause soft-tissue infections produce higher levels of PVL than

156 Necrotizing soft tissue infections represent a group of highly letha

157 Care for patients with necrotizing soft tissue infection requires a team approach with expe

158 roup G streptococcus can produce necrotising soft tissue infections resembling those produced by grou

159 0DeltasaeR/S) in murine models of sepsis and soft-tissue infection revealed that this sensory system

160 smaller series of patients with necrotizing soft tissue infections, similar analyses of risk factors

161 olonization of cases and subsequent skin and soft tissue infection (SSTI) in cases and household cont

162 rrent infection, in which S. aureus skin and soft tissue infection (SSTI) strongly protected against

163 lukF-PV was present in 36% of skin and soft tissue infection (SSTI)-derived methicillin-suscept

164 istant Staphylococcus aureus (MRSA) skin and soft tissue infection (SSTI).

165 ogical agents of community-acquired skin and soft tissue infection (SSTI).

166 ant Staphylococcus aureus (CO-MRSA) skin and soft tissue infections (SSTI) are associated with SCCmec

167 tained from pediatric patients with skin and soft tissue infections (SSTI) from Taipei did not carry

168 MRSA) is currently a major cause of skin and soft tissue infections (SSTI) in the United States.

169 s (CA-MRSA) is a prevalent cause of skin and soft tissue infections (SSTI), but the association betwe

170 has been associated previously with skin and soft-tissue infection (SSTI) and with carriage of staphy

171 s (MRSA) after community-onset MRSA skin and soft-tissue infection (SSTI) remain unclear.

172 t (ED) visit or hospitalization for skin and soft-tissue infection (SSTI), respiratory infection, int

173 aureus frequently causes recurrent skin and soft-tissue infection (SSTI).

174 as emerged as an important cause of skin and soft-tissue infections (SSTI).

175 subtropics with S. aureus-positive skin and soft tissue infections (SSTIs) and 124 control patients

176 RSA) lineage causes the majority of skin and soft tissue infections (SSTIs) and is highly associated

177 ccus aureus is the leading cause of skin and soft tissue infections (SSTIs) and mounting antibiotic r

178 n which we identified patients with skin and soft tissue infections (SSTIs) and randomized them to re

179 Recurrent Staphylococcus aureus skin and soft tissue infections (SSTIs) are common despite detect

180 other nontuberculous mycobacterial skin and soft tissue infections (SSTIs) associated with handling

181 empirical therapy for patients with skin and soft tissue infections (SSTIs) caused by molecularly and

182 All skin and soft tissue infections (SSTIs) cultured in the Cook Coun

183 The incidence of skin and soft tissue infections (SSTIs) has increased dramaticall

184 is causing an increasing number of skin and soft tissue infections (SSTIs) in Denmark and other Euro

185 illin-susceptible, has been causing skin and soft tissue infections (SSTIs) in epidemic proportions a

186 istant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs) in high-risk community se

187 USA300 has led to a high burden of skin and soft tissue infections (SSTIs) in the United States, yet

188 A-MRSA) has become a major cause of skin and soft tissue infections (SSTIs) in the US.

189 ncreasingly important as a cause of skin and soft tissue infections (SSTIs), particularly abscesses,

190 tive bacteria cause the majority of skin and soft tissue infections (SSTIs), resulting in the most co

191 aureus is the most common cause of skin and soft tissue infections (SSTIs), yet sex bias in suscepti

192 aphylococcus aureus strains causing skin and soft tissue infections (SSTIs).

193 005 guidelines for the treatment of skin and soft tissue infections (SSTIs).

194 Skin and soft-tissue infections (SSTIs) are an important cause of

195 Skin and soft-tissue infections (SSTIs) caused by community-assoc

196 tion coding system, epidemiology of skin and soft-tissue infections (SSTIs) has conflated abscess wit

197 ave increased the overall number of skin and soft-tissue infections (SSTIs), increasing the overall d

198 nds and 136 non-IFI wounds (63 with skin and soft tissue infections [SSTIs] and 73 without) were exam

199 solates from infective endocarditis (IE) and soft tissue infections (STIs), we sought to (1) validate

200 nearly twice as common in community skin and soft tissue infections than in nosocomial bloodstream in

201 itoneal necrotizing fasciitis is an uncommon soft tissue infection that is often fatal.

202 n 1750 developed nonlethal necrotic skin and soft tissue infections that healed spontaneously after 1

203 ) is a rapidly progressive, life-threatening soft-tissue infection that is traditionally caused by gr

204 Among patients with skin or soft-tissue infections, therapy to which the infecting s

205 Clinical manifestations range from skin and soft tissue infection to pneumonia with sepsis.

206 de spectrum of disease ranging from skin and soft tissue infections to life-threatening pneumonia and

207 uman disease ranging from localized skin and soft tissue infections to potentially lethal systemic in

208 ecutive patients with documented necrotizing soft tissue infections, treated at a single institution

209 l infection rates and rates of RTI, skin and soft-tissue infection, urinary tract infection, and bloo

210 The proportion of operations for skin and soft tissue infections was highest during natural disast

211 However, the frequency of serious skin and soft tissue infections was increased in anti-TNF-treated

212 In contrast, the rate of serious skin and soft tissue infections was increased, suggesting an impo

213 The presence of skin or soft-tissue infection was predictive for CA-MRSA, and th

214 pically similar virulence defect in skin and soft tissue infection, we sought to determine the relati

215 Most procedures for skin and soft tissue infections were minor (76%), whereas most op

216 Skin and soft tissue infections were more common among community-

217 Operations for skin and soft tissue infections were the most common (64%), follo

218 Patients with a stoma, fistula, or soft-tissue infection were excluded.

219 For other soft tissue infections, when antibiotic susceptibility d

220 of the isolates were recovered from skin and soft tissue infections, whereas the remaining isolates (

221 hil deployment protected mice against lethal soft tissue infection with Streptococcus pyogenes and pr

222 The risk for MRSA skin and soft tissue infection within 3 months after documented c